Depression
Depression
Search
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Company History | Corporate Profile | Boehringer Ingelheim US
Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
New Swine Vaccine Combination Released | Boehringer Ingelheim US
Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.
What can the Patient do?
What can the Patient do?
SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US
Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
Candice is moving to Germany
Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US
Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.
Obesity
Obesity
Federal and State Laws
Federal and State Laws
About Us
Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
Express Scripts Adds BI Products to Roster | BI US
Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.
Boehringer Ingelheim to unveil oncology research at WCLC
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Retinal Diseases
Retinal Diseases
FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD
FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD
Full results from EMPERIAL exercise ability trials presented
Full results from EMPERIAL exercise ability trials presented
Our Commitment
Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d
Help in all situations in life
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
Leadership
At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Global Careers Page | Boehringer Ingelheim
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials